In no uncertain terms, a federal judge in Manhattan dismissed with prejudice an antitrust suit by a Russian drugmaker who accused three rivals of an elaborate conspiracy to keep its biosimilar cancer drugs out of the U.S. market.

It was a thorough win for a dream team of lawyers from Latham & Watkins; Davis Polk & Wardwell and Gibson, Dunn & Crutcher, crushing potentially explosive allegations against their clients.

St. Petersburg-based Biocad, represented by Feinstein and Partners, sued F. Hoffman La Roche; its subsidiary Genetech Inc. and R-Pharm JSC, claiming that they tried to sabotage its efforts to sell biosimilar versions of Roche's blockbuster drugs Avastin, Herceptin and Rituxan.